NASDAQ: ZYBTZhengye Biotechnology Holding Ltd Stock
$2.01-0.02 (-0.99%)
Updated Dec 12, 2025
ZYBT Price
$2.01
Fair Value Price
N/A
Market Cap
$95.26M
52 Week Low
$1.40
52 Week High
$14.30
P/E
N/A
P/B
2.25x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.47
Operating Cash Flow
N/A
Beta
1.5
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ZYBT Overview
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its products to Vietnam, Pakistan, and Egypt. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ZYBT's potential to beat the market
- ZYBT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
ZYBT
RankedUnranked of 57
RankedUnranked of 57
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.58 | A | |
| $48.63 | A | |
| $35.56 | A |
Be the first to know about important ZYBT news, forecast changes, insider trades & much more!
ZYBT News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ZYBT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ZYBT is poor value based on its book value relative to its share price (2.25x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.25x)
P/B vs Industry Valuation
ZYBT's short-term assets ($28.49M) exceed its short-term liabilities ($19.07M)
Short-term Liabilities Financials
ZYBT's short-term assets ($28.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more ZYBT due diligence checks available for Premium users.
Valuation
ZYBT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.25x
Industry
2.25x
ZYBT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ZYBT's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$70.2M
Liabilities
$19.4M
Debt to equity
0.47
ZYBT's short-term assets ($28.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZYBT's short-term assets ($28.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZYBT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
ZYBT vs Pharmaceutical Stocks
Zhengye Biotechnology Holding Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.